Can Retatrutide Cause Cancer? Thyroid Risk, Class Effects, and What We Don't Know

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 13 sources cited

Investigational drug notice

Retatrutide is investigational and not FDA-approved. It is not legally available outside clinical trials. FormBlends does not sell, supply, prescribe, or facilitate access to retatrutide. This article discusses cancer-related questions because they appear frequently in patient inquiries. The discussion is informational. Anyone with concerns about cancer risk and weight-loss pharmacotherapy should discuss with their prescribing clinician.

Strong compliance framing

The honest position: cancer risk from incretin-class drugs is not fully resolved by available data. Some specific contraindications are well established (medullary thyroid carcinoma history, MEN 2 syndrome). For other potential cancer signals, current evidence in the FDA-approved class members has been reassuring but is not definitive. Retatrutide has even less data than approved class members because it has not been on the market or in long-term trials. The current evidence supports use in appropriate patients for the approved class drugs while ongoing surveillance continues.

Key Takeaways

• The GLP-1 class carries a boxed warning for thyroid C-cell tumors based on rodent studies; the warning applies to all approved class members (Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda, Victoza)
• Personal or family history of medullary thyroid carcinoma (MTC) and multiple endocrine neoplasia type 2 (MEN 2) are absolute contraindications for FDA-approved GLP-1 class drugs
• Retatrutide phase 2 (48 weeks, 338 patients) was too short and too small to detect cancer signals
• Post-marketing surveillance of semaglutide, tirzepatide, and liraglutide has not produced clear evidence of elevated human cancer risk over years of widespread use
• Weight loss itself reduces risk of at least 13 obesity-related cancers per IARC, which may produce a favorable net cancer balance for many patients

Direct answer

The cancer question for retatrutide cannot be definitively answered yet. Phase 2 trial data is too short to detect cancer signals beyond background rates. The drug is in the same general class as approved GLP-1 medications that carry a thyroid C-cell tumor warning based on rodent studies. Whether this translates to elevated human cancer risk has not been clearly shown in post-marketing data for approved class members. For patients with medullary thyroid carcinoma or MEN 2 history, the class is contraindicated. For other patients, the balance of evidence currently supports cautious use of approved class drugs in appropriate clinical situations. Retatrutide, when and if approved, will likely carry similar labeling and similar uncertainty.

Table of contents

1. The thyroid C-cell story in rodents
2. Why the rodent finding may not translate to humans
3. The FDA boxed warning and what it actually says
4. Post-marketing data for approved GLP-1 drugs
5. Pancreatic cancer and the pancreas-incretin question
6. Other cancers under investigation
7. The obesity-cancer relationship and net risk
8. The retatrutide-specific data gap
9. Who should not take incretin drugs
10. What to do if you have a thyroid nodule
11. The contrary view: maybe the warning is undertreated, not overstated
12. FAQ
13. Sources

The thyroid C-cell story in rodents

The thyroid concern with the GLP-1 class begins with rodent toxicology studies. In rats and mice exposed to liraglutide, semaglutide, and other incretin agonists at high doses for prolonged periods, investigators observed:

• Dose-dependent increases in thyroid C-cell hyperplasia
• Some progression to C-cell adenomas
• Some progression to medullary thyroid carcinoma (MTC)
• Effects were dose-dependent and duration-dependent

C-cells are the parafollicular cells of the thyroid that produce calcitonin. They are anatomically and functionally distinct from the follicular cells that produce thyroid hormone. C-cell malignancies (medullary thyroid carcinoma) are a small percentage of all thyroid cancers in humans, accounting for roughly 1-2% of thyroid cancer cases.

The rodent findings drove the FDA to require a boxed warning on the labeling of all approved GLP-1 class drugs, with contraindications for patients with personal or family history of MTC or MEN 2 syndrome (the inherited syndrome that predisposes to MTC).

Why the rodent finding may not translate to humans

Several features of rodent biology may make rodents particularly susceptible to GLP-1-induced thyroid C-cell effects in ways that humans are not:

• C-cell density. Rats and mice have many more C-cells in the thyroid than humans. Adult human thyroids contain very few C-cells, mostly in a small region of the gland
• GLP-1 receptor expression. Rodent C-cells express high levels of GLP-1 receptors. Human C-cells express GLP-1 receptors at much lower levels, possibly absent in some individuals
• Pharmacokinetics. Rodent toxicology studies use doses many times higher than therapeutic human doses
• Background C-cell biology. Rats have a higher baseline rate of C-cell hyperplasia and tumors than humans, especially with age

These differences suggest the rodent finding may overestimate human risk. However, they do not eliminate it. The FDA chose to label conservatively given the uncertainty.

The FDA boxed warning and what it actually says

The boxed warning on Wegovy, Ozempic, Mounjaro, Zepbound, and similar labels reads approximately:

"In rodents, [drug name] causes thyroid C-cell tumors at clinically relevant exposures. It is unknown whether [drug] causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans, as the human relevance of [drug]-induced rodent thyroid C-cell tumors has not been determined. [Drug] is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2."

The practical implication: clinicians should ask about MTC and MEN 2 family history before prescribing. Patients with such history are not candidates for the class. Other patients should be counseled about the uncertain risk and instructed to report symptoms suggestive of thyroid mass (neck lump, persistent hoarseness, swallowing difficulty).

Post-marketing data for approved GLP-1 drugs

Liraglutide has been on the market since 2010 (Victoza) and 2014 (Saxenda). Semaglutide has been available since 2017 (Ozempic) and 2021 (Wegovy). Tirzepatide since 2022 (Mounjaro) and 2023 (Zepbound). The cumulative exposure across the class runs into tens of millions of patient-years.

Several large pharmacovigilance and observational studies have examined thyroid cancer rates in GLP-1 users:

• FDA Adverse Event Reporting System (FAERS) signal analyses have shown some elevated reporting rates of thyroid cancers among GLP-1 users, but reporting biases (selective reporting, channeling bias) make these difficult to interpret
• A 2022 French nationwide cohort study (Bezin et al., Diabetes Care) reported an elevated thyroid cancer hazard ratio of approximately 1.6 with GLP-1 receptor agonist use in patients with type 2 diabetes, with the signal stronger for medullary thyroid carcinoma
• A 2024 Scandinavian cohort study using national registries did not replicate the French finding, raising methodologic questions
• Randomized trial meta-analyses have not shown statistically significant elevated cancer risk, but the trials individually have small numbers of cancer events

The honest synthesis: the post-marketing thyroid cancer signal is real but small and contested. It is not large enough to override the established cardiometabolic benefits for most appropriate patients, but it warrants continued surveillance and the existing contraindication for MTC and MEN 2 history.

Pancreatic cancer and the pancreas-incretin question

The pancreas is a second area of cancer concern with the GLP-1 class. Incretin drugs affect pancreatic islet biology directly. Early post-marketing reports (2010-2014) raised concern about pancreatitis and pancreatic cancer.

Subsequent investigation has been reassuring but not conclusive:

• FDA and EMA reviews in 2014-2015 did not find clear evidence of elevated pancreatic cancer risk after detailed pancreatic tissue analysis from organ donors
• Large meta-analyses of randomized cardiovascular outcome trials (including LEADER, SUSTAIN-6, REWIND) have not shown statistically elevated pancreatic cancer rates
• Some observational studies have continued to suggest small elevated risk; others have not

The current expert consensus is that pancreatic cancer risk from the GLP-1 class is at most small and may be zero. Acute pancreatitis remains a labeled warning that occurs at higher rates than placebo in trials.

Other cancers under investigation

Several other cancer types have been examined for class signals:

• Breast cancer. Earlier pooled analyses of liraglutide trials suggested a small elevated signal. Larger subsequent analyses have not confirmed it
• Colorectal cancer. Some observational studies have suggested elevated risk; others have suggested reduced risk (possibly through weight-loss-mediated mechanisms). The net signal is unclear
• Renal cell carcinoma. No clear signal in available data
• Cholangiocarcinoma. Some signals in earlier surveillance, possibly related to GLP-1 effects on gallbladder physiology
• Hepatic cancer. No clear signal; possibly reduced risk through MASLD/MASH improvement

Continued surveillance is appropriate. None of these signals have risen to the level of changing labeling or clinical recommendations.

The obesity-cancer relationship and net risk

Obesity is itself an established risk factor for at least 13 cancers per the International Agency for Research on Cancer (IARC):

• Postmenopausal breast cancer
• Endometrial cancer
• Ovarian cancer
• Colorectal cancer
• Renal cell carcinoma
• Liver cancer (including HCC)
• Pancreatic cancer
• Esophageal adenocarcinoma
• Gastric cardia cancer
• Gallbladder cancer
• Multiple myeloma
• Meningioma
• Thyroid cancer (papillary subtype, follicular cancers)

Meaningful sustained weight loss reduces risk of several of these cancers, though the time scale to clinically detectable risk reduction is years to decades. The benefit is not immediate.

The net cancer calculus for an individual patient depends on baseline weight, baseline cancer risk factors, family history, and the degree and duration of weight loss achieved. For many patients with obesity, the cancer-protective effects of sustained weight loss likely outweigh the small theoretical thyroid and pancreatic concerns. This is the implicit reasoning behind FDA approval of these drugs despite the labeled cancer warnings.

The retatrutide-specific data gap

Retatrutide-specific cancer data is essentially absent. The phase 2 trial enrolled 338 patients for 48 weeks. Background cancer rates in adults age 45-65 (the typical trial demographic) are roughly 0.5-1% per year. Across 338 patient-years of follow-up, the expected number of cancer events is around 2-4 cases. Detecting an elevated cancer risk above this background requires either much larger samples or much longer follow-up, neither of which the phase 2 trial provided.

The TRIUMPH phase 3 program will enroll more patients and follow them longer. Cancer events will be reported as part of safety analyses. Even phase 3 data will be insufficient to fully characterize cancer risk; that requires post-marketing surveillance over years.

Patients considering retatrutide if and when approved should understand: the cancer risk picture will not be fully clear at the time of approval. Initial labeling will likely include the thyroid C-cell warning (based on rodent class effect) and possibly cautions about pancreatic effects. Other potential signals will be characterized over time.

Who should not take incretin drugs

Based on current FDA labeling for approved class members, contraindications include:

• Personal history of medullary thyroid carcinoma (MTC)
• Family history of medullary thyroid carcinoma (first-degree relative)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2A or MEN 2B)
• Hypersensitivity to the drug or excipients

Relative cautions where additional discussion is warranted:

• History of pancreatitis (especially recurrent)
• Severe gastroparesis or gastric outlet obstruction
• Active gallbladder disease
• Pregnancy or active attempts to conceive
• Breastfeeding

Retatrutide's eventual labeling will specify its own contraindications. Based on shared mechanism, the MTC and MEN 2 contraindication will almost certainly carry over.

What to do if you have a thyroid nodule

Thyroid nodules are common (palpable in ~5% of adults; detectable by ultrasound in 20-50% of adults). Most are benign. For patients considering incretin therapy who have known thyroid nodules:

• Characterize the nodule before starting (ultrasound, TI-RADS classification, fine-needle aspiration if criteria met)
• If benign, incretin therapy is generally compatible with continued thyroid surveillance
• If indeterminate or suspicious, complete workup before starting
• If medullary thyroid carcinoma is suspected or confirmed, incretin therapy is contraindicated

Routine pre-treatment thyroid ultrasound or calcitonin measurement is not currently recommended as standard of care. The labeled approach is symptom-based vigilance plus contraindication for known MTC/MEN 2 history.

The contrary view: maybe the warning is undertreated, not overstated

The discussion above has emphasized that the rodent thyroid signal may not translate to humans, that post-marketing data has been broadly reassuring, and that the cancer-protective effects of weight loss likely outweigh small theoretical risks. A reasonable counterargument runs the other direction.

Detection lag. Medullary thyroid carcinoma is slow-growing. Even if GLP-1 drugs were causing increased MTC incidence at small rates, detection in post-marketing data would lag the actual rise by 5-10 years. Tens of millions of patient-years of exposure looks substantial but may be too short to detect a slow-emerging signal.

Combined exposures. Patients increasingly stay on incretin drugs for years (often indefinitely as obesity is a chronic condition). Cumulative lifetime exposure is much larger than typical clinical trial duration. Risk per patient-year may be very small, but multiplied across decades of treatment, individual lifetime risk could be meaningful.

Replication challenges. The French study (Bezin 2022) showed elevated thyroid cancer risk; subsequent Scandinavian work did not replicate. The reasonable interpretation is that the signal exists in some populations and not in others, possibly reflecting differences in baseline cancer surveillance, healthcare utilization patterns, or unmeasured confounding. A genuinely null finding would be expected to replicate cleanly across multiple large datasets.

Triple agonist novelty. Retatrutide adds glucagon receptor activity not present in the existing approved class. Glucagon signaling in oncology is incompletely characterized. New cancer signals could emerge that do not parallel the existing GLP-1 class.

The honest position synthesizing both views: the existing FDA-approved class probably has small elevated thyroid cancer risk in some populations, balanced against substantial cancer-protective effects from weight loss. The net is probably favorable for most appropriate patients but not zero. Retatrutide carries the same uncertainty plus the additional uncertainty of the novel glucagon component. Anyone considering retatrutide (once approved) or current class drugs should understand the uncertainty exists and discuss with their clinician.

FAQ

Does retatrutide cause thyroid cancer in humans? Unknown. The trial duration is too short to detect cancer signals. Class effects suggest possible small elevated risk for medullary thyroid carcinoma specifically.

What is MTC? Medullary thyroid carcinoma. A specific type of thyroid cancer arising from C-cells. Accounts for 1-2% of thyroid cancers. Often associated with inherited MEN 2 syndrome.

What is MEN 2? Multiple endocrine neoplasia type 2. An inherited syndrome that predisposes to medullary thyroid carcinoma, pheochromocytoma, and parathyroid disease.

Should I get a calcitonin level before starting? Routine pre-treatment calcitonin testing is not standard of care and has high false positive rates. Clinical history-based screening for MTC and MEN 2 is the standard approach.

Are there safer weight-loss medications? All weight-loss medications have labeled risks. Phentermine-topiramate (Qsymia) and naltrexone-bupropion (Contrave) do not carry GLP-1 class thyroid warnings but have their own risk profiles.

Does the cancer risk apply to compounded versions? Compounded semaglutide and tirzepatide contain the same active ingredient as branded products. The mechanism-based concerns apply equally. Compounded products carry additional risks (purity, identity, stability) on top of the class concerns.

Will retatrutide carry a boxed warning? Almost certainly yes, given the shared mechanism class. Specific labeling will be finalized at approval.

What symptoms should I watch for? Neck lump, persistent hoarseness, difficulty swallowing, new neck pain. These are not specific for thyroid cancer but warrant evaluation.

Can I take a GLP-1 drug if I have papillary thyroid cancer history? Papillary thyroid cancer is distinct from medullary thyroid carcinoma. The labeled contraindication is specifically for MTC and MEN 2. Patients with papillary cancer history should still discuss with their oncologist and prescribing clinician, but the strict contraindication does not apply.

Should I tell my clinician about distant relatives with thyroid cancer? Yes, especially first-degree relatives. The contraindication is for personal or family history of medullary specifically, but family history of any thyroid cancer is worth discussing.

Related guides

• Does Retatrutide Cause Cancer
• Retatrutide and Thyroid: Side Effects, Risks and How to Manage (2026)
• Does Retatrutide Cause Thyroid Problems
• Retatrutide and Thyroid Medullary Carcinoma Risk
• Retatrutide for People with Thyroid Conditions: What You Need to Know
• Does Retatrutide Affect Testosterone or Libido? What the Class Data Suggests

Sources

1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. New England Journal of Medicine. 2023;389:514-526.
2. Bjerre Knudsen L et al. Glucagon-like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation. Endocrinology. 2010.
3. Bezin J, Gouverneur A, Penichon M, et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care. 2022;46:384-390.
4. Pasternak B et al. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ. 2024.
5. Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). NEJM. 2016.
6. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). NEJM. 2016.
7. Gerstein HC et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). The Lancet. 2019.
8. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM. 2023.
9. International Agency for Research on Cancer. IARC Handbooks of Cancer Prevention, Volume 16: Body Fatness. 2018.
10. FDA. Wegovy (semaglutide) Prescribing Information, including Boxed Warning.
11. FDA. Zepbound (tirzepatide) Prescribing Information, including Boxed Warning.
12. FDA. Saxenda (liraglutide) Prescribing Information, including Boxed Warning.
13. National Comprehensive Cancer Network Clinical Practice Guidelines: Thyroid Carcinoma, 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a telehealth platform that matches patients with independent licensed providers and U.S.-based pharmacies. Cancer-related screening, risk assessment, and contraindication review are clinical responsibilities of the prescribing provider, not FormBlends.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are produced by state-licensed 503A compounding pharmacies in response to individual prescriptions. They are not FDA-approved and are not interchangeable with branded products. The boxed warnings on branded products apply mechanistically to compounded versions as well, since the active ingredient is identical.

Investigational Drug Notice. Retatrutide is investigational and not FDA-approved. FormBlends does not sell, supply, or facilitate access to retatrutide. Cancer-related discussion on this page is informational and references published trial data, post-marketing surveillance of approved class members, and oncology epidemiology literature.

Results Disclaimer. Cancer risk is influenced by genetics, lifestyle, environmental exposures, age, sex, family history, and many other factors. Drug-attributable cancer risk, when present, is typically small relative to these other factors. Individualized risk assessment with a clinician is appropriate for anyone considering pharmacotherapy with cancer-related warnings.

Trademark Notice. Wegovy, Ozempic, Saxenda, and Victoza are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly, or any pharmaceutical manufacturer.